# CJC-1295 (no DAC)

> Modified GHRH(1-29) analog with short plasma half-life.

- Also known as: Modified GRF (1-29), Mod GRF 1-29
- Class: Growth Hormone
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/cjc-1295-no-dac

## Overview

CJC-1295 without DAC is a 30-amino-acid analog of GHRH(1-29) with four substitutions that improve stability against DPP-4. Half-life ~30 minutes; commonly studied alongside GHRPs for pulsatile GH release.

CJC-1295 without DAC — also called Modified GRF(1-29) — is a 30-amino-acid analog of the first 29 residues of growth-hormone-releasing hormone (GHRH). Four amino-acid substitutions improve stability against the enzyme DPP-4 while preserving GHRH-receptor activity.

Without the Drug Affinity Complex (DAC), its plasma half-life is short — on the order of 30 minutes — so it produces a brief GH pulse. It is commonly studied alongside a GHRP such as ipamorelin, where the two receptor classes act synergistically. It is not FDA-approved.

## Mechanism

GHRH receptor agonism on pituitary somatotrophs.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular formula | C165H269N47O46 |
| Molecular weight | 3647.2 Da |
| PubChem CID | [91971820](https://pubchem.ncbi.nlm.nih.gov/compound/91971820) |

## Sequence

```
YADAIFTQSYRKVLAQLSARKLLQDIMSR
```

## Research areas

Studied in: GH pulsatility, Body composition models.

Guides on this site:

- [Growth Hormone & Body Composition](https://www.americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.

## Key research

- Pulsatile GH release — GHRH-receptor agonism studied for short, physiologic GH pulses.
- DPP-4 resistance — substitutions extend stability versus native GHRH(1-29).
- GHRP synergy — frequently paired with ghrelin-receptor agonists for amplified release.
- Body composition — examined in models for lean-mass and fat endpoints.
- Not FDA-approved — research compound.

## FAQs

### What is CJC-1295 (no DAC)?

It is a stabilized GHRH(1-29) analog (Modified GRF 1-29) studied for short, pulsatile growth-hormone release.

### What does "no DAC" mean?

DAC (Drug Affinity Complex) is an albumin-binding addition that greatly extends half-life. Without it, the peptide acts briefly, producing a short GH pulse.

### Why is it studied with GHRPs?

GHRH analogs and ghrelin-receptor agonists (GHRPs) act on different receptors; combining them is studied for synergistic GH release.

### Is it approved?

No — it is a research compound, not FDA-approved. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning CJC-1295, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity](https://clinicaltrials.gov/study/NCT00267527) — TERMINATED · PHASE2 · NCT00267527

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/cjc-1295-no-dac
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.